CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Algorae Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Algorae Pharmaceuticals Ltd
L 7 330 Collins St
Phone: +61 289990970p:+61 289990970 MELBOURNE, VIC  3000  Australia Ticker: 1AI1AI

Business Summary
Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board David R.Hainsworth 1/5/2023 10/30/2022
Chief Financial Officer DayaUka
Chief Operating Officer BelindaDi Bartolo 12/13/2021 12/13/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
1AI
LCT
Living Cell Technologies Ltd.
LVCLY

General Information
Number of Employees: 48 (As of 6/30/2008)
Outstanding Shares: 1,686,239,419 (As of 12/31/2023)
Shareholders: 2,638
Stock Exchange: ASX
Fax Number: +61 396024709


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024